In a crucial development this week in the ongoing multidistrict litigation against Merck & Co., a federal judge in North Carolina granted the plaintiffs’ motion to compel adverse reaction data for the company’s Gardasil HPV-vaccine, which faces challenges to both its safety and efficacy.

The plaintiffs have alleged adverse effects from the vaccine, such as neurological and autoimmune diseases such as Postural orthostatic tachycardia syndrome (POTS).  Merck is also accused of intentionally misrepresenting Gardasil’s value.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]